A total of 24 small molecule drugs targeting TYMS were predicted, including Raltitrexed, Floxuridine, Pemetrexed, Capecitabine, Fluorouracil (Supplementary Table S5), contributing to the development of new therapeutic targets for dialysis patients heart failure. The gene discussed is TYMS; the disease is heart failure.